Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Aesthetics M & A

QUOTED. 1 July 2019. Rick Gonzalez.

  • News

Executive Summary

AbbVie is set to enter the medical aesthetics space with its surprise announcement to buy Allergan for about $63bn in a cash and stock transaction. See what AbbVie's CEO Rick Gonzalez said about it here.

"With increasing interest and acceptability of aesthetic procedures and products globally and increasing utilization within younger demographics, the medical aesthetics market has the potential to double by 2025, making this franchise extremely attractive and durable for AbbVie." – Rick Gonzalez, CEO, AbbVie

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Aesthetics M & A
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT125300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By